Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

Completed · Phase 3

Conditions studied: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma

In brief

This clinical trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) works in detecting prostate cancer that has come back (recurrent) in patients after initial therapy. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET/CT, may help doctors detect tumors that have come back after initial therapy.

Key facts

Study ID
NCT02940262
Run by
Jonsson Comprehensive Cancer Center
People needed
1138
Starts
2016-09-15
Expected to finish
2021-06-18
Last updated by the study team
2021-07-02

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.